Skip to content

effect of sublingual Misoprostol in inducing labor

A comparison between sublingual Misoprostol and intravenous Oxytocin for inducing labor in women at term

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201205089636N1
Enrollment
70
Registered
2012-05-28
Start date
2011-11-19
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Indication for terminating pregnancy with low Bishop score. Disorders related to length of gestation and fetal growth

Interventions

Intervention 1: Intervention group: sublingual Misoprostol. Intervention 2: Control group: intravenous Oxytocin.
Treatment - Drugs
Intervention group: sublingual Misoprostol
Control group: intravenous Oxytocin

Sponsors

Vice-chancellor for research,Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria were gestational age 37 - 42 weeks, Bishop Score = 4), gestational age less than 37 and more than 42, non-vertex presentation, intrauterine demise, previous uterine surgery, oligo or polyhydramnios, intrauterine growth retardation, multiple pregnancy, clinical evidence of cardiopulmonary collapse, electrolyte abnormalities, severe pre-eclampsia/eclampsi, hepatitis, asthma, glaucoma and adrenal insufficiency ,

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Indication for terminating pregnancy with unfavorable contractures and cervix. Timepoint: Every 15 minutes. Method of measurement: Physical examination.

Secondary

MeasureTime frame
Vaginal delivery vs caesarian section. Timepoint: At the end of delivery. Method of measurement: Patients medical record.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLaleh Ghadirian

Tehran University of Medical Sciences

lghadirian@razi.tums.ac.ir , lalehghadirian@yahoo.com+98 913 314 1409

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026